JAGSNPHARM vs VIYASH: Stock Comparison

JAGSONPAL PHARMACEUTICALS vs VIYASH SCIENTIFICUpdated 11 Sept 26, 4:08 PM ISTNSE & company filings

VIYASH SCIENTIFIC is the larger company by market capitalisation. JAGSONPAL PHARMACEUTICALS shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

JAGSNPHARM leads 10; VIYASH leads 3 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

JAGSNPHARMVIYASH

Valuation lens

What price are you paying?

Market CapContext only
₹1,537 Cr
₹11,228 Cr
P/E RatioJAGSNPHARM has the lower reading
34.02x
61.63x
P/B RatioVIYASH has the lower reading
5.64x
3.86x
EPSJAGSNPHARM has the higher reading
₹2
₹1.51
Book ValueContext only
₹41.95
₹71.3
Dividend YieldJAGSNPHARM has the higher reading
2.78%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
VIYASH is the larger company
₹11,228 Cr vs ₹1,537 Cr
P/E Ratio
JAGSNPHARM has a lower P/E
34.02x vs 61.63x
P/B Ratio
VIYASH has a lower P/B
3.86x vs 5.64x
EPS
JAGSNPHARM has higher earnings per share
₹2 vs ₹1.51
Dividend Yield
JAGSNPHARM has a higher dividend yield
2.78% vs 0%
Revenue Growth (TTM YoY)
JAGSNPHARM has faster revenue growth
9.6% vs 0%
EPS Growth (TTM YoY)
JAGSNPHARM has faster EPS growth
23.8% vs 0%
Qtr Sales Growth
VIYASH has stronger quarterly sales growth
167.57% vs -71.37%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricJAGSNPHARMVIYASH
SectorHealthcare
IndustryPharmaceuticals

Price

MetricJAGSNPHARMVIYASH
Live Price₹232.89₹257.6
Day Change-0.04%-1.09%
Volume51,42118.6 L
52-Week High₹264.5₹298
52-Week Low₹155₹178.13
Distance from 52W High-11.95%-13.56%

Valuation

MetricJAGSNPHARMVIYASH
Market Cap₹1,537 Cr₹11,228 Cr
P/E Ratio34.02x61.63x
P/B Ratio5.64x3.86x
EPS₹2₹1.51
Book Value₹41.95₹71.3
Dividend Yield2.78%0%

Growth

MetricJAGSNPHARMVIYASH
Revenue Growth (TTM YoY)9.6%0%
EPS Growth (TTM YoY)23.8%0%
Qtr Sales Growth-71.37%167.57%
Qtr Profit Growth-69.39%279.02%

Profitability & Leverage

MetricJAGSNPHARMVIYASH
ROE15.6%4.88%
ROCE16.48%4.99%
Net Margin15%6.57%
Operating Margin20.38%11.72%
Debt to Equity0x0.14x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricJAGSNPHARMVIYASH
Promoter Holding25.55% 0.43 pp0%
FII Holding2.3% 0.14 pp4.5% 1.56 pp
DII Holding0.62% 0.4 pp3.75% 4.24 pp
Public Holding28.03% 1.42 pp30.34% 2.67 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: JAGSONPAL PHARMACEUTICALS and VIYASH SCIENTIFIC.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.